- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05977712
Circadian Rhythm and Other Factors in Memory Clinic Patients (CIRCAME)
Circadian Rhythm and Other Individual Factors Among Memory Clinic Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The diagnosis of Alzheimer's disease and other related dementias is mainly based on assessment of cognitive, behavioral and neuropsychological symptoms, functional limitations and imaging data/cerebrospinal fluid (CSF) biomarkers in some cases. These measures are primarily used in specialized clinics leading to a potential large number of dementia cases not being diagnosed. With population ageing, the number of people living with dementia is increasing and there is an urgent need for cost-effective, scalable tool for early, accurate screening of dementia cases, including both AD and other types of dementia, in primary care. Furthermore, the factors associated with the progression of the different types of dementia are still poorly understood, limiting the prospects for intervention to improve the quality of life of patients and their caregivers and to slow the progression of the disease.
This project aims to identify circadian rhythm components and other individual risk factors that could be used in primary care for dementia diagnosis (including its subtypes: AD, Lewy bodies, vascular, frontotemporal dementia) and stages (cognitively healthy, mild cognitive impairment, clinical dementia). A secondary objective is to determine factors associated with progression of the disease, in terms of cognitive decline and limitations in activities of daily living, as well as progression to dementia among cognitively healthy controls and patients with mild cognitive impairment.
This will be achieved using data from 1500 patients from 2 memory clinics in Paris from who data on sociodemographic, behavioral, and health related factors (such as reported sleep disturbance, plasma biomarkers, retina measures (in a subsample, CIRCAME-EYE)) will be measured at inclusion interview. Baseline examination will also include a wrist-mounted device for a measure of circadian rhythm and its related behaviors (physical activity and sleep), for which disruptions are thought to characterize dementia subtypes and stages. Information on dementia diagnosis and stages will come from memory clinic routine visits at the time of the inclusion; they will include subtypes (AD, Lewy bodies, vascular, frontotemporal dementia), cognitive stages (cognitively healthy, mild cognitive impairment, clinical dementia) and AD stages based on CSF biomarkers and clinical measures. Information on progression of the disease (change in cognitive function using the mini-mental status examination, change in limitations in activity of daily living) and incidence of dementia, institutionalization and mortality will be retrieved from patients' routine visits at memory clinics up to 15 years after the inclusion period.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Claire PAQUET, MDPhD
- Phone Number: 33 0140054313
- Email: claire.paquet@aphp.fr
Study Contact Backup
- Name: Séverine SABIA, PhD
- Phone Number: 33 0157279046
- Email: severine.sabia@inserm.fr
Study Locations
-
-
-
Paris, France, 75010
- Recruiting
- Centre de neurologie Cognitive / CMRR
-
Contact:
- Claire PAQUET, MDPhD
- Phone Number: 33 0140054313
- Email: claire.paquet@aphp.fr
-
Paris, France, 75018
- Recruiting
- Hôpital de Jour Gériatrique et consultation mémoire
-
Contact:
- Sophie LACAILLE, MDPhD
- Phone Number: 33 0153111701
- Email: sophie.lacaille@aphp.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient of legal age (18 or over)
- Signed informed consent form
- Patient affiliated to the french social security system
Exclusion Criteria:
- Skin allergy to plastic
- Diagnosis of psychiatric disorder that can explain all cognitive symptoms
- Inability to come accompanied for patients with a Mini-Mental State Examination (MMSE) cognitive score ≤20 or a clinician assessment indicating the need to be accompanied (e.g. wheelchair use, agitation)
- Patient of legal age and subject to a legal protection measure (guardianship, curatorship)
- Participation at the time of inclusion and during the 9-day period of wearing the accelerometer in interventional research with potential impact on circadian rhythm
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
CIRCAME
This is the full cohort of patients that compose the CIRCAME study (N estimated = 1500)
|
The questionnaire includes information on socio-demographics (age, sex, education, occupation, marital status), behavioural (smoking, alcohol consumption, social functioning), and health-related factors (morbidities, treatment, sleep disturbance, eye diseases, frailty, falls).
This includes earing test, cognitive tests (mini-mental status examination, MemScreen), body mass index, waist circumference, blood pressure and blood tests (biomarkers of Alzheimer's disease, neurodegeneration, and other dementias).
Participants will be wearing an accelerometer for 9 days.
|
CIRCAME-EYE ancillary study
Patients from CIRCAME seen at the Fernand-Widal hospital who will also undergo an eye examination (CIRCAME-EYE, N estimated = 1100, a sub-group of CIRCAME)
|
The questionnaire includes information on socio-demographics (age, sex, education, occupation, marital status), behavioural (smoking, alcohol consumption, social functioning), and health-related factors (morbidities, treatment, sleep disturbance, eye diseases, frailty, falls).
This includes earing test, cognitive tests (mini-mental status examination, MemScreen), body mass index, waist circumference, blood pressure and blood tests (biomarkers of Alzheimer's disease, neurodegeneration, and other dementias).
Participants will be wearing an accelerometer for 9 days.
Eye fundus photo, OCT and OCT-A exams
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dementia subtypes and stages
Time Frame: At inclusion (2024-2025), in 2026 and every 3 years up to 2042
|
Dementia subtypes and stages will be defined on routine visits at the memory center and categorised as: Alzheimer's disease, vascular dementia, Lewy body dementia, frontotemporal dementia), as having mild cognitive impairment (differentiating AD form of MCI and others), or being cognitively healthy. This outcome will be examined cross-sectionally first (at inclusion) and, among those with MCI and healthy controls, prospectively over time (up to 15 years after the inclusion period). |
At inclusion (2024-2025), in 2026 and every 3 years up to 2042
|
Alzheimer's disease stages
Time Frame: At inclusion (2024-2025), in 2026 and every 3 years up to 2042
|
AD stages will be based on CSF Aβ peptide level (Aβ42/40 ratio) to assess the A+ criterion, p-Tau 181 to assess the T+ criterion, and clinical examination to assess the CogFI+ criterion (cognitive impairment and/or neurobehavioural symptoms with functional impact on daily life). This analysis will be among those with CSF biomarkers measured as part of their routine visit at the memory clinics. |
At inclusion (2024-2025), in 2026 and every 3 years up to 2042
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fluid based biomarkers of dementia
Time Frame: At inclusion
|
Association of the different exposure variables with plasma and csf biomarkers of dementia will be examined. Plasma biomarkers include 1) Amyloid β 42/40 ratio, a marker of AD pathology, although probably less robust than the CSF Aβ 42/40 ratio; 2) phosphorylated tau (p-tau) for detection of early AD-related tauopathy and disease staging; 3) neurofilament light (NfL), a marker of neurodegeneration in all neurodegenerative diseases, and 4) glial fibrillary acidic protein (GFAP), a marker of astrocytosis, found as early as in pre-amyloid AD disease stages. CSF biomarkers include Aβ42 and Aβ40 peptides, total and phosphorylated tau proteins (when done in routine care). |
At inclusion
|
Cognitive function
Time Frame: At inclusion (2024-2025), and change between inclusion and 2026 and every 3 years up to 2042
|
Cognitive tests include the mini-mental status examination test and the MemScreen test.
They will be evaluated at inclusion and during routine visit at the memory clinics.
Association with scores at inclusion and changes between inclusion and several time points will be examined.
|
At inclusion (2024-2025), and change between inclusion and 2026 and every 3 years up to 2042
|
Limitations in activity of daily living (ADL) and instrumental activity of daily living (IADL)
Time Frame: At inclusion (2024-2025), and change between inclusion and 2026 and every 3 years up to 2042
|
Limitations in ADL (dressing, walking, bathing, eating, continence, using toilet) and IADL (cooking, shopping for grocery, telephone calls, taking medication, using transports, managing money).
|
At inclusion (2024-2025), and change between inclusion and 2026 and every 3 years up to 2042
|
Institutionalization, hospitalization and death
Time Frame: Incidence between inclusion and 2026 and every 3 years up to 2042
|
Information will come from memory clinics and electronic health records.
|
Incidence between inclusion and 2026 and every 3 years up to 2042
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- APHP230740
- 2023-A01469-36 (Other Identifier: ID-RCB number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dementia
-
University of North Carolina, Chapel HillNational Institute on Aging (NIA)CompletedAlzheimer Dementia | Dementia Alzheimers | CaregiverUnited States
-
Temple UniversityRecruitingDementia | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
Hebrew SeniorLifeRecruitingAging | Alzheimer Dementia | Presenile Alzheimer DementiaUnited States
-
Temple UniversityRecruitingDementia | Alzheimer Disease | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
Cognito Therapeutics, Inc.Enrolling by invitationExtension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)Cognitive Impairment | Alzheimer Disease | Mild Cognitive Impairment | Dementia Alzheimers | Dementia of Alzheimer Type | AD | Dementia, Mild | Dementia ModerateUnited States
-
University College, LondonNot yet recruitingDementia | Dementia, Vascular | Dementia, Mixed | Dementia With Lewy Bodies | Dementia of Alzheimer Type | Dementia Moderate | Dementia Severe | Dementia Frontal | DEM
-
University College, LondonThe University of Hong KongUnknownDementia | Dementia, Vascular | Dementia, Mixed | Dementia With Lewy Bodies | Dementia of Alzheimer Type | Dementia Moderate | Dementia Severe | Dementia Frontal
-
National Tainan Junior College of NursingCompletedCognitive Impairment | Dementia, Mild | Dementia ModerateTaiwan
-
Karen RobertoNational Institute on Aging (NIA)RecruitingDementia | Dementia Alzheimers | Neuro-Degenerative Disease | Dementia of Alzheimer Type | Dementia SevereUnited States
-
Karolinska InstitutetRegion Stockholm; KTH Royal Institute of TechnologyActive, not recruitingAlzheimer Dementia | Dementia DisordersSweden
Clinical Trials on Questionnaire
-
H. Lee Moffitt Cancer Center and Research InstituteSan Diego State University; University of Minnesota; University of ArizonaCompletedAnxiety | Psychological StressUnited States
-
Centre Hospitalier Universitaire de NiceCompletedGeneral Population | TDAH | Children Aged 5 to 18 YearsFrance
-
Imperial College LondonRoyal Marsden NHS Foundation Trust; University College London Hospitals; The... and other collaboratorsCompleted
-
Minneapolis Veterans Affairs Medical CenterUnited States Department of DefenseCompletedLower Limb Amputation Below Knee (Injury) | Lower Limb Amputation Above Knee (Injury)United States
-
NSABP Foundation IncNational Cancer Institute (NCI)Completed
-
Stanford UniversityRecruitingAstigmatism | Nearsightedness | FarsightednessUnited States
-
University of LiegeCompletedCritical Illness | Covid19 | Psychological Stress | FamilyBelgium
-
Imperial College Healthcare NHS TrustNot yet recruitingCervical Myelopathy
-
Rabin Medical CenterCompleted
-
National Taiwan University HospitalNational Taiwan UniversityUnknownComputerized Physician Order EntryTaiwan